The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.
Ouyang DJ, Chen QT, Anwar M, Xie N, Ouyang QC, Fan PZ, Qian LY, Chen GN, Zhou EX, Guo L, Gu XW, Ding BN, Yang XH, Liu LP, Deng C, Xiao Z, Li J, Wang YQ, Zeng S, Wang S, Yi W.
Ouyang DJ, et al.
Front Pharmacol. 2021 Aug 26;12:682568. doi: 10.3389/fphar.2021.682568. eCollection 2021.
Front Pharmacol. 2021.
PMID: 34512325
Free PMC article.